Views & Analysis Healthcare evidence development: guilty until proven innocen... Pharma must prepare its case meticulously to support its new drug applications.
Views & Analysis Behind the buzz of real-world data and real-world evidence Putting the who, where and why of real-world studies into context.
Views & Analysis Integrating patient insights and real-world data: the future... Drugs development in 2017 looks very different to how it did 10 years ago, and it’s still evolving.
Views & Analysis A new age: the real-world development pathway Pharma must be prepared to work collaboratively to establish the best benefit-risk profiles and outcomes.
Views & Analysis Outcomes-based medicine demands real-world evidence RWE must become a fundamental accompaniment to traditional RCT data.
Views & Analysis A novel UK approach to cancer access: yes, no, or maybe? Experts discuss the implications of the new, reinvigorated Cancer Drugs Fund, for pharma and patients.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.